Daily Recap - WEDNESDAY
Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →What's hot
View all perspectives
What's Hot
EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Bimekizumab in Active AS: 5 Year Study
Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cannabinoid Receptor in RA Patients
Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Treatments in SpA
Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.
Watch video →
PR3+ in Lupus Nephritis
Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Simulated Trials to Counter ORAL Survelliance
Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Difficult to Treat axSpA
Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Window of Opportunity in PsA
Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
TMP SMX Prophylaxis in GPA
Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The FOREMOST Study: Apremilast in PsA
Dr. Peter Nash reports on abstract 1691 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
Watch video →
Real World Experience with PEXIVAS Low Steroid Taper
Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read more →
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Read more →
Effects of Apremilast on Cardiometabolic Effects in PsA
Dr. Peter Nash discusses abstract 1414 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
An Interview with Kevin Winthrop: Three Questions About COVID 19
Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA.
Watch video →
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Dr. Rachel Tate
2 years ago
#ACR23 Abs #0505 found use of IL-17 inhibitors and oral DMARD alone were associated with a decreased likelihood of achieving MDA in PsA. Small sample size, but interesting finding nonetheless. https://t.co/CAZGykwxRT @rheumnow https://t.co/8ptF8aTIFu
Adela Castro AdelaCastro222
2 years ago
💡RP is a heterogeneous disease.
💡Think VEXAS in RP with MDS.
💡Think MAGIC if oral/genital ulcers.
💡Pts are experts on their own disease! Listen and acknowledge their symptoms. Shout out to Dr @maferradastrong
#ACR23 #ImNotYellingImColombian🇨🇴
@ACRheum @RheumNow https://t.co/nTZ96pJh09
Adela Castro AdelaCastro222
2 years ago
💡Screen pts with Ssc for ILD with HRCT at diagnosis.
💡“MCTD” may meet criteria for Ssc dont look away at the positive U1RNP!
💡Kidney biopsy in SRC =Time is of the essence.
💡Cardiac involvement is 2nd cause of mortality screen with echo annually. @fboinMD #ACR23 @RheumNow https://t.co/yp3yjqqeQv
Dr. Antoni Chan
2 years ago
How can we maximise digital health to improve outcomes. Come and visit my poster session today and it will be good to meet IRL. I’m presenting poster #0507 using digital e-PROMs to measure disease activity in psoriatic arthritis #digital Abst #0507 #ACR23 @RheumNow https://t.co/R9LX8H9X0E
Dr. Rachel Tate
2 years ago
#ACR23 Abs 0484 found higher hs-CRP levels helped identify PsO pts at high risk of future development of PsA. Unclear timeline, but this may help to early ID referrals to rheum. https://t.co/4JRsI6iEgI @rheumnow https://t.co/sXNwyL87Ud
Dr. Rachel Tate
2 years ago
Pain, itch, and fatigue associated with decreased work productivity/impairment in PsA and PsO pts. #ACR23 considerations for treatment for these pts should include these factors. Abs #0488 https://t.co/mLG5ohFopQ @rheumnow https://t.co/8ANL4pcxM2
Md Yuzaiful Md Yusof
2 years ago
#ACR23 Abstr#PP12 "I am stronger than my disease & won’t let it stop me from leading a fulfilling life!"- a person with #Sjogren shared tips on lifestyle modification to help fatigue.
- schedule appointments in the morning
- exercise
- keep a diary
- listen to body
@RheumNow https://t.co/8ROFrDvPS1
Dr. Rachel Tate
2 years ago
Do you check fecal calprotectin levels in your SpA pts? Maybe you should. #ACR23 Abs #0495 EISER study shows increased prevalence of undiagnosed IBD in SpA that may be detected in our clinics with fecal calprotectin levels prior to GI evaluation. https://t.co/d7BbrUd570 @rheumnow https://t.co/COcKdvjWnr
Dr. John Cush RheumNow
2 years ago
RheumNow’s expanded coverage of the #ACR23 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification. My goal when attending any conference is to learn as much as I can, synthesize that information, and bring you clinically relevant morsels for you to consider for your practice.
Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs for rheumatoid arthritis. The challenge remains on how best to characterise the subtypes of RA in order to choose the best drug to ensure optimal outcome for patients.
sheila
2 years ago
AI is here to stay, like it or not.
Some words to ponder on👇
#ACR23 @RheumNow @rheumarhyme https://t.co/2K3Qc0Il8i
Bella Mehta bella_mehta
2 years ago
Low uptake of Artificial intelligence in Medicine! This needs to change. Keynote speaker #ACR23 @RheumNow https://t.co/gOTu1wBnZS
sheila
2 years ago
"Machines don't decide, they make predictions..-Dr. Avi Goldfarb
As a parting note, he leaves the audience some Qs: "In your orgs/institutions, how much of what you do is really about delivering value? Or serving patients & other stakeholders?"
#ACR23 @RheumNow @rheumarhyme https://t.co/xnFeQgDPco
David Liew drdavidliew
2 years ago
This is what exactly what AI should mean for clinical rheumatologists:
discard the mundane & repetitive
enhance/make time the value add
Rheumatologists are really good at the value add, and we dislike the mundane & repetitive. We should embrace what is to come.
#ACR23 @RheumNow https://t.co/6Lb2ihlPFF
Poster Hall